Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's SERM lasofoxifene headed for US panel review

This article was originally published in Scrip

Executive Summary

The US FDA's reproductive health drugs advisory panel will meet on September 8th to consider Pfizer's selective oestrogen receptor modulator (SERM) Fablyn (lasofoxifene, formerly Oporia) for the treatment of osteoporosis. This is Pfizer's third attempt to get the troubled SERM, developed with Ligand Pharmaceuticals, approved in the US. The company originally filed lasofoxifene for osteoporosis prevention in August 2004, but the FDA issued a non-approvable letter. Pfizer's second proposed indication, vaginal atrophy, was also rejected. The NDA submitted last December for treatment in postmenopausal women at increased fracture risk contains three-year interim data from the Phase III, 8,556 patient PEARL study. Lilly's Evista (raloxifene) is the only SERM approved for osteoporosis. Wyeth has had trouble getting its SERM bazedoxifene licensed in the US, having received two approvable letters for a prevention indication and one for treatment.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts